<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04562467</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00043561</org_study_id>
    <nct_id>NCT04562467</nct_id>
  </id_info>
  <brief_title>The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk</brief_title>
  <acronym>IPE-PREVENTION</acronym>
  <official_title>The Icosapent Ethyl and Prevention of Vascular Regenerative Cell Exhaustion Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Medical and Surgical Knowledge Translation Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HLS Therapeutics, Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Unity Health Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Western Ontario, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Medical and Surgical Knowledge Translation Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      IPE-PREVENTION is a prospective, randomized, 3-month long, open-label study. A total of 70&#xD;
      individuals with elevated cardio-metabolic risk and heightened triglyceride levels, and who&#xD;
      are on stable statin therapy will be randomized (1:1) to receive either icosapent ethyl (IPE)&#xD;
      2g BID or standard of care.&#xD;
&#xD;
      It is hypothesized that assignment to IPE will lower progenitor cell depletion as well as&#xD;
      limit progenitor cell dysfunction. This study may offer some molecular and cellular insights&#xD;
      into the mechanisms underlying the cardiovascular benefits of IPE therapy reported in the&#xD;
      REDUCE-IT trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The development and natural history of atherothrombosis involves the pathophysiological&#xD;
      interplay between inflammation, dyslipidemia, oxidative stress and endothelial dysfunction.&#xD;
      Unregulated, these processes culminate in endothelial dysfunction, and ultimately&#xD;
      cardio-metabolic chronic diseases. Aberrant lipid oxidation due to elevated triglycerides and&#xD;
      cholesterol primes and activates innate immune cell activity resulting in elevated&#xD;
      inflammation and oxidative stress.&#xD;
&#xD;
      The randomized, placebo-controlled REDUCE-IT trial enrolled individuals with established&#xD;
      atherosclerotic heart disease, or diabetes and an additional risk factor, who were on&#xD;
      pre-existing statin therapy with persistent hypertriglyceridemia. REDUCE-IT reported that the&#xD;
      group allocated to the omega-3 fatty acid icosapent ethyl (IPE; 2g BID) exhibited a 25%&#xD;
      relative risk reduction for the primary composite endpoint of CV death, nonfatal myocardial&#xD;
      infarction, nonfatal stroke, coronary revascularization, or unstable angina, and a 20%&#xD;
      decreased risk of CV death when compared to standard of care. Vascepa® (IPE) is currently&#xD;
      approved by Health Canada and the U.S. FDA for the reduction of cardiovascular risk in&#xD;
      statin-treated individuals with elevated triglycerides who are either at heightened&#xD;
      cardiovascular risk or who have diabetes and at least one risk factor.&#xD;
&#xD;
      The exact mechanism through which IPE decreased cardiovascular events in REDUCE-IT has not&#xD;
      yet been elucidated.&#xD;
&#xD;
      The population and function of circulating pro-vascular progenitor cells have been shown to&#xD;
      benefit from diminished lipid oxidation, inflammation and oxidative stress. A healthy&#xD;
      population of circulating pro-vascular progenitor cells in turn affords timely and efficient&#xD;
      blood vessel repair, regeneration and atheroprotection.&#xD;
&#xD;
      The omega-3 fatty acid eicosapentaenoic acid (EPA) has been reported to inhibit M1 macrophage&#xD;
      polarization in a murine model and increase human endothelial progenitor cell (EPC) colony&#xD;
      formation and functionality in vitro. In vivo, EPA levels have been observed to correlate&#xD;
      significantly with circulating EPC number (CD34+CD133+VEGFR2+ cells). Collectively, these&#xD;
      findings affirm that EPA, and potentially omega-3 fatty acids, can enhance the number and&#xD;
      function of circulating pro-vascular progenitor cells and can alter M1/M2 macrophage balance&#xD;
      towards a regenerative blood vessel phenotype.&#xD;
&#xD;
      IPE-PREVENTION is a prospective, 3-month long, open-label study that will randomize a total&#xD;
      of 70 individuals with elevated cardio-metabolic risk and heightened triglyceride levels and&#xD;
      who are on stable statin therapy to either IPE 2g BID or standard of care. Blood samples will&#xD;
      be collected at the baseline and month 3 visits for evaluations of cell populations in the&#xD;
      blood as well as measurements of biomarkers that contribute to the proinflammatory and&#xD;
      pro-oxidant milieu of individuals at elevated cardio-metabolic risk. The study will utilize&#xD;
      the AldefluorTM assay to differentiate between and enumerate hematopoietic progenitor cells,&#xD;
      EPCs, granulocyte precursors and macrophage precursors. The overarching goal would be to&#xD;
      document how assignment to IPE and standard-of-care impact on circulating progenitor cell&#xD;
      depletion and dysfunction. The effect of IPE exposure on the inflammatory and oxidative&#xD;
      profile will also be assessed.&#xD;
&#xD;
      The results of this investigation may offer some molecular and cellular insights into the&#xD;
      mechanisms underlying the cardiovascular benefits of IPE therapy reported in the REDUCE-IT&#xD;
      trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>20% change in the mean frequency of ALDHhiSSChi granulocyte precursor cells in individuals treated with IPE compared to SOC for 3-months</measure>
    <time_frame>Baseline - 3 months post-randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>40% change in the ratio of M1:M2 monocyte precursor cells in individuals treated with IPE compared to SOC for 3-months. M1 monocyte precursor cells defined as ALDHhiSSCmidCD14+CD86+ and M2 monocyte precursor cells defined as ALDHhiSSCmidCD14+CD163+</measure>
    <time_frame>Baseline - 3 months post-randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>20% change in the mean frequency of ALDHhiSSCloCD133+ cells with pro-vascular progenitor cells phenotype in individuals treated with IPE compared to SOC for 3-months.</measure>
    <time_frame>Baseline - 3 months post-randomization</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in the concentration of serum oxidative stress markers from baseline to the 3-month visit in individuals treated with IPE compared to SOC</measure>
    <time_frame>Baseline - 3 months post-randomization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in the concentration of serum inflammatory markers from baseline to the 3-month visit in individuals treated with IPE compared to SOC</measure>
    <time_frame>Baseline - 3 months post-randomization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in the number of ALDHhiSSClo Myeloid Colony Forming Units (CFU) from baseline to the 3-month visit in vitro</measure>
    <time_frame>Baseline - 3 months post-randomization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in the activity of myeloperoxidase harvested from ALDHhiSSChi granulocytes from baseline to the 3-month visit in vitro</measure>
    <time_frame>Baseline - 3 months post-randomization</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Cardiovascular Risk Factor</condition>
  <condition>Triglycerides High</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Icosapent Ethyl + Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Icosapent Ethyl 1000 MG Oral Capsule [Vascepa] 2 x 1g capsules BID (4g total) as per REDUCE-IT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care therapy (including statin therapy as per inclusion criteria)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]</intervention_name>
    <description>2 x 1g capsules BID as per REDUCE-IT</description>
    <arm_group_label>Icosapent Ethyl + Standard of Care</arm_group_label>
    <other_name>Vascepa</other_name>
    <other_name>IPE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women ≥65 years of age and men ≥40 years of age with established CVD (see criterion&#xD;
             'a' below) or ≥50 years of age with diabetes and one additional CV risk factor (see&#xD;
             criterion 'b' below)&#xD;
&#xD;
               1. Those with established CVD should have ≥1 of the following clinical history&#xD;
&#xD;
                    -  Documented coronary artery disease (CAD)&#xD;
&#xD;
                         -  Prior MI&#xD;
&#xD;
                         -  Multivessel CAD (≥50% stenosis in ≥2 major epicardial coronary&#xD;
                            arteries)&#xD;
&#xD;
                         -  Hospitalization for high-risk non-ST-segment elevation acute coronary&#xD;
                            syndrome&#xD;
&#xD;
                    -  Documented cerebrovascular or carotid disease (≥1 of the following)&#xD;
&#xD;
                         -  Prior ischemic stroke&#xD;
&#xD;
                         -  Carotid artery disease with ≥50% stenosis&#xD;
&#xD;
                         -  History of carotid revascularization&#xD;
&#xD;
                    -  Documented peripheral artery disease (≥1 of the following)&#xD;
&#xD;
                         -  Ankle-brachial index (ABI) &lt;0.9 with symptoms of intermittent&#xD;
                            claudication&#xD;
&#xD;
                         -  History of aorto-iliac or peripheral arterial intervention&#xD;
&#xD;
               2. Those with a history of diabetes (either type 1 or type 2 diabetes mellitus) but&#xD;
                  no CVD should also have ≥1 of the following:&#xD;
&#xD;
                    -  Cigarette smoker or stopped smoking within 3 months before the baseline&#xD;
                       visit&#xD;
&#xD;
                    -  Documented hypertension OR on antihypertensive agents&#xD;
&#xD;
                    -  HDL-C ≤1.0 mmol/L for men or ≤1.3 mmol/L for women&#xD;
&#xD;
                    -  High sensitivity C-reactive protein &gt;3.0 mg/L&#xD;
&#xD;
                    -  eGFR 30 to 60 mL/min/1.73m2&#xD;
&#xD;
                    -  Documented micro- or macro-albuminuria&#xD;
&#xD;
                    -  Retinopathy&#xD;
&#xD;
                         -  Non-proliferative retinopathy&#xD;
&#xD;
                         -  Preproliferative or proliferative retinopathy&#xD;
&#xD;
                         -  Maculopathy&#xD;
&#xD;
                         -  Advanced diabetic retinopathy&#xD;
&#xD;
                         -  History of photocoagulation&#xD;
&#xD;
                    -  ABI &lt;0.9 without symptoms of intermittent claudication&#xD;
&#xD;
          2. Elevated triglycerides (≥1.5 mmol/L but &lt;5.6 mmol/L)&#xD;
&#xD;
          3. On stable statin therapy for ≥4 weeks at the baseline visit&#xD;
&#xD;
          4. Willing to provide written informed consent and be compliant with the study&#xD;
             requirements&#xD;
&#xD;
          5. Willing and able to follow the diet recommended by the study doctor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participation in another clinical trial with an investigational agent ≤90 days prior&#xD;
             to screening&#xD;
&#xD;
          2. Women who are of childbearing potential&#xD;
&#xD;
          3. Any condition or therapy which the study doctor thinks might pose a risk to the&#xD;
             participant&#xD;
&#xD;
          4. Severe (New York Heart Association class IV) heart failure&#xD;
&#xD;
          5. Any life-threatening disease expected to result in death within the next 2 years&#xD;
&#xD;
          6. Diagnosis or laboratory evidence of active severe liver disease&#xD;
&#xD;
          7. HbA1c &gt;10.0% at the baseline visit&#xD;
&#xD;
          8. SBP ≥200 mmHg or DBP ≥100 mmHg (despite being on antihypertensive therapy)&#xD;
&#xD;
          9. Planned coronary intervention or any non-cardiac major surgical procedure&#xD;
&#xD;
         10. Known familial lipoprotein lipase deficiency, apolipoprotein C-II deficiency, or&#xD;
             familial dysbetalipoproteinemia&#xD;
&#xD;
         11. Statin intolerant or hypersensitivity to statin therapy&#xD;
&#xD;
         12. Require peritoneal dialysis or hemodialysis&#xD;
&#xD;
         13. eGFR &lt;30 mL/min/1.73m2&#xD;
&#xD;
         14. History of atrial fibrillation&#xD;
&#xD;
         15. History of major bleeding event(s)&#xD;
&#xD;
         16. Documented history of pancreatitis&#xD;
&#xD;
         17. Malabsorption syndrome and/or chronic diarrhea&#xD;
&#xD;
         18. Known acquired immunodeficiency syndrome&#xD;
&#xD;
         19. Unexplained elevated creatine kinase concentration &gt;5 × the upper limits of normal or&#xD;
             elevation due to known muscle disease&#xD;
&#xD;
         20. Use of niacin, fibrates, omega-3 fatty acids, dietary supplements containing omega-3&#xD;
             fatty acids, bile acid sequestrants or PCSK9 inhibitors&#xD;
&#xD;
         21. Known hypersensitivity to fish and/or shellfish, or ingredients of IPE&#xD;
&#xD;
         22. Inability to swallow IPE capsules whole&#xD;
&#xD;
         23. Drug or alcohol abuse within the past 6 months, and inability/unwillingness to abstain&#xD;
             from drug abuse and excessive alcohol consumption during the study&#xD;
&#xD;
         24. Mental/psychological concerns or any other reason to expect difficulty in complying&#xD;
             with the study requirements or understanding the goal and potential risks of being a&#xD;
             part of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Subodh Verma, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unity Health Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David A Hess, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Robarts Research Institute, London, Ontario</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Deepak L Bhatt, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Brigham and Women's Hospital, Boston, Massachusetts</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ehab Bakbak, BSc</last_name>
    <phone>9057679127</phone>
    <email>ehab.bakbak@mail.utoronto.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniella C Terenzi, PhD</last_name>
    <email>daniella.terenzi@mail.utoronto.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>North York Diagnostic and Cardiac Centre</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <zip>M6B 1N6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Oshawa Clinic</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1H 1B9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asaad Bakbak, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diagnostic Assessment Centre</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1S4N6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Subodh Verma, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Langstaff Medical Clinic</name>
      <address>
        <city>Vaughan</city>
        <state>Ontario</state>
        <zip>L4L 0K8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin A Terenzi, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Mechanick JI, Farkouh ME, Newman JD, Garvey WT. Cardiometabolic-Based Chronic Disease, Adiposity and Dysglycemia Drivers: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Feb 11;75(5):525-538. doi: 10.1016/j.jacc.2019.11.044. Review.</citation>
    <PMID>32029136</PMID>
  </reference>
  <reference>
    <citation>Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 Jun;9(6):653-60. Review.</citation>
    <PMID>12778163</PMID>
  </reference>
  <reference>
    <citation>Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10.</citation>
    <PMID>30415628</PMID>
  </reference>
  <reference>
    <citation>Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest. 1999 May;103(9):1231-6. Review.</citation>
    <PMID>10225965</PMID>
  </reference>
  <reference>
    <citation>Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA, Rafii S. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood. 2000 Feb 1;95(3):952-8.</citation>
    <PMID>10648408</PMID>
  </reference>
  <reference>
    <citation>Takamura M, Kurokawa K, Ootsuji H, Inoue O, Okada H, Nomura A, Kaneko S, Usui S. Long-Term Administration of Eicosapentaenoic Acid Improves Post-Myocardial Infarction Cardiac Remodeling in Mice by Regulating Macrophage Polarization. J Am Heart Assoc. 2017 Feb 21;6(2). pii: e004560. doi: 10.1161/JAHA.116.004560.</citation>
    <PMID>28223437</PMID>
  </reference>
  <reference>
    <citation>Devaraj S, Chien A, Rao B, Chen X, Jialal I. Modulation of endothelial progenitor cell number and function with n-3 polyunsaturated fatty acids. Atherosclerosis. 2013 May;228(1):94-7. doi: 10.1016/j.atherosclerosis.2013.02.036. Epub 2013 Mar 13.</citation>
    <PMID>23528830</PMID>
  </reference>
  <reference>
    <citation>Morishita T, Uzui H, Ikeda H, Amaya N, Kaseno K, Ishida K, Fukuoka Y, Lee JD, Tada H. Association of CD34/CD133/VEGFR2-Positive Cell Numbers with Eicosapentaenoic Acid and Postprandial Hyperglycemia in Patients with Coronary Artery Disease. Int J Cardiol. 2016 Oct 15;221:1039-42. doi: 10.1016/j.ijcard.2016.07.079. Epub 2016 Jul 5.</citation>
    <PMID>27447811</PMID>
  </reference>
  <reference>
    <citation>Capoccia BJ, Robson DL, Levac KD, Maxwell DJ, Hohm SA, Neelamkavil MJ, Bell GI, Xenocostas A, Link DC, Piwnica-Worms D, Nolta JA, Hess DA. Revascularization of ischemic limbs after transplantation of human bone marrow cells with high aldehyde dehydrogenase activity. Blood. 2009 May 21;113(21):5340-51. doi: 10.1182/blood-2008-04-154567. Epub 2009 Mar 26.</citation>
    <PMID>19324906</PMID>
  </reference>
  <reference>
    <citation>Putman DM, Liu KY, Broughton HC, Bell GI, Hess DA. Umbilical cord blood-derived aldehyde dehydrogenase-expressing progenitor cells promote recovery from acute ischemic injury. Stem Cells. 2012 Oct;30(10):2248-60. doi: 10.1002/stem.1206.</citation>
    <PMID>22899443</PMID>
  </reference>
  <reference>
    <citation>Terenzi DC, Al-Omran M, Quan A, Teoh H, Verma S, Hess DA. Circulating Pro-Vascular Progenitor Cell Depletion During Type 2 Diabetes: Translational Insights Into the Prevention of Ischemic Complications in Diabetes. JACC Basic Transl Sci. 2018 Nov 5;4(1):98-112. doi: 10.1016/j.jacbts.2018.10.005. eCollection 2019 Feb.</citation>
    <PMID>30847424</PMID>
  </reference>
  <reference>
    <citation>Hess DA, Terenzi DC, Trac JZ, Quan A, Mason T, Al-Omran M, Bhatt DL, Dhingra N, Rotstein OD, Leiter LA, Zinman B, Sabongui S, Yan AT, Teoh H, Mazer CD, Connelly KA, Verma S. SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus. Cell Metab. 2019 Oct 1;30(4):609-613. doi: 10.1016/j.cmet.2019.08.015. Epub 2019 Aug 30.</citation>
    <PMID>31477497</PMID>
  </reference>
  <reference>
    <citation>Balber AE. Concise review: aldehyde dehydrogenase bright stem and progenitor cell populations from normal tissues: characteristics, activities, and emerging uses in regenerative medicine. Stem Cells. 2011 Apr;29(4):570-5. doi: 10.1002/stem.613. Review.</citation>
    <PMID>21308868</PMID>
  </reference>
  <reference>
    <citation>Gentry T, Foster S, Winstead L, Deibert E, Fiordalisi M, Balber A. Simultaneous isolation of human BM hematopoietic, endothelial and mesenchymal progenitor cells by flow sorting based on aldehyde dehydrogenase activity: implications for cell therapy. Cytotherapy. 2007;9(3):259-74.</citation>
    <PMID>17464758</PMID>
  </reference>
  <reference>
    <citation>Shoulars K, Noldner P, Troy JD, Cheatham L, Parrish A, Page K, Gentry T, Balber AE, Kurtzberg J. Development and validation of a rapid, aldehyde dehydrogenase bright-based cord blood potency assay. Blood. 2016 May 12;127(19):2346-54. doi: 10.1182/blood-2015-08-666990. Epub 2016 Mar 11.</citation>
    <PMID>26968535</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 13, 2020</study_first_submitted>
  <study_first_submitted_qc>September 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2020</study_first_posted>
  <last_update_submitted>September 18, 2021</last_update_submitted>
  <last_update_submitted_qc>September 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiometabolic Risk</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Icosapent Ethyl</keyword>
  <keyword>Omega-3</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Progenitor Cells</keyword>
  <keyword>Vascular Disease</keyword>
  <keyword>Blood Lipids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eicosapentaenoic acid ethyl ester</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

